Unknown

Dataset Information

0

Xpert Mycobacterium tuberculosis/Rifampicin-Detected Rifampicin Resistance is a Suboptimal Surrogate for Multidrug-resistant Tuberculosis in Eastern Democratic Republic of the Congo: Diagnostic and Clinical Implications.


ABSTRACT:

Background

Rifampicin (RIF) resistance is highly correlated with isoniazid (INH) resistance and used as proxy for multidrug-resistant tuberculosis (MDR-TB). Using MTBDRplus as a comparator, we evaluated the predictive value of Xpert MTB/RIF (Xpert)-detected RIF resistance for MDR-TB in eastern Democratic Republic of the Congo (DRC).

Methods

We conducted a cross-sectional study involving data from new or retreatment pulmonary adult TB cases evaluated between July 2013 and December 2016. Separate, paired sputa for smear microscopy and MTBDRplus were collected. Xpert testing was performed subject to the availability of Xpert cartridges on sample remnants after microscopy.

Results

Among 353 patients, 193 (54.7%) were previously treated and 224 (63.5%) were MTBDRplus TB positive. Of the 224, 43 (19.2%) were RIF monoresistant, 11 (4.9%) were INH monoresistant, 53 (23.7%) had MDR-TB, and 117 (52.2%) were RIF and INH susceptible. Overall, among the 96 samples detected by MTBDRplus as RIF resistant, 53 (55.2%) had MDR-TB. Xpert testing was performed in 179 (50.7%) specimens; among these, 163 (91.1%) were TB positive and 73 (44.8%) RIF resistant. Only 45/73 (61.6%) Xpert-identified RIF-resistant isolates had concomitant MTBDRplus-detected INH resistance. Xpert had a sensitivity of 100.0% (95% CI, 92.1-100.0) for detecting RIF resistance but a positive-predictive value of only 61.6% (95% CI, 49.5-72.8) for MDR-TB. The most frequent mutations associated with RIF and INH resistance were S531L and S315T1, respectively.

Conclusions

In this high-risk MDR-TB study population, Xpert had low positive-predictive value for the presence of MDR-TB. Comprehensive resistance testing for both INH and RIF should be performed in this setting.

SUBMITTER: Bisimwa BC 

PROVIDER: S-EPMC8282324 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Xpert Mycobacterium tuberculosis/Rifampicin-Detected Rifampicin Resistance is a Suboptimal Surrogate for Multidrug-resistant Tuberculosis in Eastern Democratic Republic of the Congo: Diagnostic and Clinical Implications.

Bisimwa Bertin C BC   Nachega Jean B JB   Warren Robin M RM   Theron Grant G   Metcalfe John Z JZ   Shah Maunank M   Diacon Andreas H AH   Sam-Agudu Nadia A NA   Yotebieng Marcel M   Bulabula André N H ANH   Katoto Patrick D M C PDMC   Chirambiza Jean-Paul JP   Nyota Rosette R   Birembano Freddy M FM   Musafiri Eric M EM   Byadunia Sifa S   Bahizire Esto E   Kaswa Michel K MK   Callens Steven S   Kashongwe Zacharie M ZM  

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20210701 2


<h4>Background</h4>Rifampicin (RIF) resistance is highly correlated with isoniazid (INH) resistance and used as proxy for multidrug-resistant tuberculosis (MDR-TB). Using MTBDRplus as a comparator, we evaluated the predictive value of Xpert MTB/RIF (Xpert)-detected RIF resistance for MDR-TB in eastern Democratic Republic of the Congo (DRC).<h4>Methods</h4>We conducted a cross-sectional study involving data from new or retreatment pulmonary adult TB cases evaluated between July 2013 and December  ...[more]

Similar Datasets

| S-EPMC9380361 | biostudies-literature
| S-EPMC4225074 | biostudies-literature
| S-EPMC7448907 | biostudies-literature
| S-EPMC9504715 | biostudies-literature
| S-EPMC8670120 | biostudies-literature
| S-EPMC8638987 | biostudies-literature
| S-EPMC11655456 | biostudies-literature
| S-EPMC4493128 | biostudies-literature
2023-03-10 | GSE226993 | GEO
| S-EPMC8638996 | biostudies-literature